Is AKRO or XYLD a better dividend investment in 2026?

AKRO currently yields 3.66% with a 5% 5-year dividend growth rate. XYLD yields 10.98% with 0.5% growth. The better choice depends on your goal: XYLD offers higher current income.

What is the dividend yield difference between AKRO and XYLD?

AKRO has a forward dividend yield of 3.66% ($2.00/share annually). XYLD yields 10.98% ($4.30/share annually). The yield gap is 7.32 percentage points.

Home › Compare › AKRO vs XYLD

AKRO vs XYLD: Dividend Comparison 2026

AKRO yields 3.66% · XYLD yields 10.98%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 AKRO wins by $72.00 in total portfolio value

INVESTMENT

TIME HORIZON10 years

AKRO

● Live price

3.66%

Share price

$54.65

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$463.02

Full AKRO calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

10.98%

Share price

$39.13

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.3K

Annual income

$3,219.02

Full XYLD calculator →

Portfolio growth — AKRO vs XYLD

📍 AKRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	AKRO	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, AKRO + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

AKRO pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKRO

Annual income on $10K today (after 15% tax)

$311.07/yr

After 10yr DRIP, annual income (after tax)

$393.57/yr

XYLD

Annual income on $10K today (after 15% tax)

$933.63/yr

After 10yr DRIP, annual income (after tax)

$2,736.17/yr

At 15% tax rate, XYLD beats the other by $2,342.60/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKRO + XYLD for your $10,000?

AKRO: 50%XYLD: 50%

100% XYLD50/50100% AKRO

Portfolio after 10yr

$25.3K

Annual income

$1,841.02/yr

Blended yield

7.27%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on AKRO right now

AKRO

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$54.67

+0.0% upside vs current

Range: $54.00 — $56.00

Altman Z

54.7

Piotroski

2/9

XYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKRO buys

XYLD buys

No recent congressional trades found for AKRO or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAKROXYLD

Forward yield	3.66%	10.98% ✓
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$25.4K ✓	$25.3K
Annual income after 10y	$463.02	$3,219.02 ✓
Total dividends collected	$4.2K	$19.6K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: AKRO vs XYLD ($10,000, DRIP)

Year	AKRO Portfolio	AKRO Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$11,066	$365.97	$10,818	$1,098.39	+$248.00 → AKRO
2	$12,219	$378.48	$11,738	$1,222.51	+$481.00 → AKRO
3	$13,465	$390.58	$12,774	$1,364.64	+$691.00 → AKRO
4	$14,810	$402.25	$13,944	$1,527.86	+$866.00 → AKRO
5	$16,260	$413.48	$15,270	$1,715.87	+$990.00 → AKRO
6	$17,822	$424.27	$16,775	$1,933.09	+$1.0K → AKRO
7	$19,505	$434.61	$18,490	$2,184.87	+$1.0K → AKRO
8	$21,314	$444.52	$20,450	$2,477.63	+$864.00 → AKRO
9	$23,260	$453.99	$22,697	$2,819.19	+$563.00 → AKRO
10	$25,352	$463.02	$25,280	$3,219.02	+$72.00 → AKRO

AKRO vs XYLD: Complete Analysis 2026

AKRO — Stock

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Full AKRO Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this AKRO vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKRO vs SCHD AKRO vs JEPI AKRO vs O AKRO vs KO AKRO vs MAIN AKRO vs QYLD AKRO vs JEPQ AKRO vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.